Please use this identifier to cite or link to this item:
Title: The polarity protein PARD3 and cancer.
Austin Authors: Atashrazm, Farzaneh;Ellis, Sarah
Affiliation: Olivia Newton-John Cancer Research Institute
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, VIC, Australia
Issue Date: 2021
Date: 2021-06-07
Publication information: Oncogene 2021; 40(25): 4245-4262
Abstract: Tissue disorganisation is one of the main hallmarks of cancer. Polarity proteins are responsible for the arrangement of cells within epithelial tissues through the asymmetric organisation of cellular components. Partition defective 3 (PARD3) is a master regulator of the Par polarity complex primarily due to its ability to form large complexes via its self-homologous binding domain. In addition to its role in polarity, PARD3 is a scaffolding protein that binds to intracellular signalling molecules, many of which are frequently deregulated in cancer. The role of PARD3 has been implicated in multiple solid cancers as either a tumour suppressor or promoter. This dual functionality is both physiologically and cell context dependent. In this review, we will discuss PARD3's role in tumourigenesis in both laboratory and clinical settings. We will also review several of the mechanisms underpinning PARD3's function including its association with intracellular signalling pathways and its role in the regulation of asymmetric cell division.
DOI: 10.1038/s41388-021-01813-6
ORCID: 0000-0003-3471-8160
Journal: Oncogene
PubMed URL: 34099863
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 30, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.